A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer
- 10 October 2014
- journal article
- Published by Springer Science and Business Media LLC in Clinical and Translational Oncology
- Vol. 17 (4), 330-338
- https://doi.org/10.1007/s12094-014-1235-1
Abstract
To identify a novel system for scoring intratumoral immune response that can improve prognosis and therapy decisions in early stage non-small cell lung cancer (NSCLC). Eighty-four completely resected stage I/II NSCLC without adjuvant therapy were classified by expression profiling using whole genome microarrays. An external cohort of 162 tumors was used to validate the results. Immune cells present in tumor microenvironment were evaluated semiquantitatively by CD20, CD79, CD3, CD8, CD4 and CD57 immunostaining. Univariate and multivariate analyses of variables associated with recurrence-free survival were performed. Initial molecular classification identified three clusters, one with significantly better RFS. A reduced two-subgroup classification and a 50-gene predictor were built and validated in an external dataset: high and low risk of recurrence patients (HR = 3.44; p = 0.001). Analysis of the predictor´s genes showed that the vast majority were related to a B/plasma cell immune response overexpressed in the low-risk subgroup. The predictor includes genes coding for unique B lineage-specific genes, functional elements or other genes that, although non-restricted to this lineage, have strong influence on B-cell homeostasis. Immunostains confirmed increased B-cells in the low-risk subgroup. Gene signature (p p Favorable prognosis in completely resected NSCLC is determined by a B-cell-mediated immune response. It can be differently scored by a 50-gene expression profile or by CD20 immunostaining. That prognosis information not reflected by traditional classifications may become a new tool for determining individualized adjuvant therapies.Keywords
This publication has 39 references indexed in Scilit:
- Colon cancer molecular subtypes identified by expression profiling and associatedto stroma, mucinous type and different clinical behaviorBMC Cancer, 2012
- A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studiesThe Lancet, 2012
- The immune score as a new possible approach for the classification of cancerJournal of Translational Medicine, 2012
- Prognostic Immune Markers in Non–Small Cell Lung CancerClinical Cancer Research, 2011
- A signature of immune function genes associated with recurrence-free survival in breast cancer patientsBreast Cancer Research and Treatment, 2011
- Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival PredictionPLOS ONE, 2010
- Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?JNCI Journal of the National Cancer Institute, 2010
- Gene expression profiles of lung adenocarcinoma linked to histopathological grading and survival but not to EGF-R status: a microarray studyBMC Cancer, 2010
- A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung CancerPLoS Medicine, 2006